Can engineered immune cells tame stubborn autoimmune diseases?

NCT ID NCT07729995

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This phase 1 trial tests an experimental cell therapy called LMY-922 (BAFF CAR-T cells) in people aged 16 to 75 with refractory autoimmune diseases, including rheumatoid arthritis, lupus, dermatomyositis, and systemic sclerosis. The therapy uses donor immune cells engineered to target BAFF, a protein involved in autoimmune attacks. The study aims to find a safe dose and see if this approach can reduce disease activity in patients who have not responded to other treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental cell therapy called BAFF CAR-T cells (LMY-922), made from donor immune cells engineered to target BAFF
What this could lead to
If it works, this could offer a new treatment option for people with autoimmune diseases that do not respond to standard therapies.
What could go wrong
This is an early phase 1 trial, so safety and effectiveness are not yet known. CAR-T cell therapies can cause serious side effects, including cytokine release syndrome and neurological issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS (DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.